InMed Pharmaceuticals
14 hedge funds and large institutions have $342K invested in InMed Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
36% less capital invested
Capital invested by funds: $536K → $342K (-$194K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$64.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.9K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
| 4 |
Millennium Management
New York
|
+$14.7K |
| 5 |
Renaissance Technologies
New York
|
+$1.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$96.6K |
| 2 |
Two Sigma Advisers
New York
|
-$54.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Two Sigma Advisers
New York
| $146K | -$54.1K | -103 | -25% |
|
|
EAM
2
Empery Asset Management
New York
| $58K | +$64.5K | +123 | New |
|
|
3
Renaissance Technologies
New York
| $43K | +$1.05K | +2 | +2% |
|
|
4
Two Sigma Investments
New York
| $37K | -$96.6K | -184 | -70% |
|
|
TSS
5
Two Sigma Securities
New York
| $17K | +$18.9K | +36 | New |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $13K | +$14.7K | +28 | New |
|
|
7
Millennium Management
New York
| $13K | +$14.7K | +28 | New |
|
8
Creative Planning
Overland Park,
Kansas
| $10K | – | – | – |
|
|
TWC
9
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $2.42K | – | – | – |
|
|
AWM
10
AllSquare Wealth Management
Albany,
New York
| $1K | – | – | – |
|
11
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
FDCDDQ
12
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $482 | – | – | – |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$14K | -22 | Closed |
|
INM Hedge Fund Activity: Q1 2022 in Review
14 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q1 2022, worth a combined $342K — down 36% from $536K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new INM positions and 1 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $64.5K. The largest seller was Two Sigma Investments, cutting an estimated $96.6K.
- 14 institutional investors held InMed Pharmaceuticals (INM) as of Q1 2022, up from 12 in Q4 2021.
- Funds reported $342K of InMed Pharmaceuticals stock for Q1 2022, down 36% quarter-over-quarter.
- 4 funds opened new InMed Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of +3 holders.
- The largest InMed Pharmaceuticals buyer in Q1 2022 was Empery Asset Management, an estimated $64.5K added.
- The largest InMed Pharmaceuticals seller in Q1 2022 was Two Sigma Investments, an estimated $96.6K sold.
Based on aggregated 13F filings for Q1 2022.